Alcon AG vs Vanguard International High Dividend Yield ETF — how do they compare? Alcon AG trades at $73.8 (market cap $36.44B), while Vanguard International High Dividend Yield ETF trades at $104.51. The key difference: Alcon AG pays a 0.48% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | VYMI | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.12 | $105.05 |
52-Week Low | $62.02 | $82.92 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.525, down 0.14% on the day, with a bullish technical signal from moving averages and positive analyst sentiment. Recent Q2 2026 earnings beat estimates, with revenue of $10.4 billion in 2025 and a net income margin of 5.92%. The company raised its 2026 profitability outlook, citing tariff relief and strong product launches.
The stock offers a 17.9% upside to the consensus price target of $86.67, supported by bullish analyst ratings and improving cash flow trends. Key risks include elevated P/E valuation at 57.52 and potential macroeconomic pressures on medical device demand. Earnings growth and execution on new products remain critical for sustained momentum.
VYMI, the Vanguard International High Dividend Yield ETF, trades at $104.48, down slightly by 0.11% today. The technical outlook is bullish based on moving averages, with key support at $104 and resistance at $105. Recent news highlights strong institutional buying and its appeal to retirees seeking international dividend income, with the fund outperforming the S&P 500 over the past five years.
The ETF offers a compelling income play with a 3.4% dividend yield and an 8.86% five-year dividend CAGR, supported by bullish analyst sentiment. Risks include currency fluctuations from international exposure and broader market volatility, but its diversification and high yield provide a defensive stance amid economic uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →